Pharmacokinetics of concentration-controlled mycophenolate mofetil in proliferative lupus nephritis: An observational cohort study

Therapeutic Drug Monitoring

Volumn 36, Issue 4, 2014, Pages 423-432

  Alexander, Suceena ^a   Fleming, Denise H ^a   Mathew, Binu S ^a   Varughese, Santosh ^a   Jeyaseelan, Visalakshi ^a   Tamilarasi, Veerasamy ^a   Jacob, Chakko K ^a   John, George T ^b  

^a CHRISTIAN MEDICAL COLLEGE   (India)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Area under the concentration time curve; Asian lupus nephritis; Concentration control; Limited sampling strategies; Mycophenolate mofetil; Therapeutic drug monitoring

Indexed keywords

MOFILET; MYCEPT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; SERUM ALBUMIN; UNCLASSIFIED DRUG; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

ADULT; AGED; APLASTIC ANEMIA; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; DRUG EXPOSURE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; INFECTION; LEUKOPENIA; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; MEASUREMENT; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; TREATMENT RESPONSE; ADOLESCENT; ANALOGS AND DERIVATIVES; DOSE RESPONSE; LUPUS NEPHRITIS; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AREA UNDER CURVE; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; YOUNG ADULT;

EID: 84904571620     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000031     Document Type: Article

References (16)

1. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl. 2012;2:139-274.
2. Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20:1103-1112.
3. Sinclair A, Appel G, Dooley MA, et al. Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS). Lupus. 2007;16:972-980.
4. Joy MS, Hilliard T, Hu Y, et al. Influence of clinical and demographic variables on mycophenolic acid pharmacokinetics in antineutrophil cytoplasmic antibody-associated vasculitis. Ann Pharmacother. 2009; 43:1020.
5. Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004;15:241-250.
6. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25: 1271-1277.
7. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461-470.
8. Kuypers DR, de Jonge H, Naesens M, et al. Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients. Clin Ther. 2008;30:673-683.
9. Fleming DH, Mathew BS, John GT, et al. A six-hour extrapolated sampling strategy for monitoring mycophenolic acid in renal transplant patients in the Indian subcontinent. J Postgrad Med. 2006;52:248-252.
10. Mathew BS, Fleming DH, Annapandian VM, et al. A reliable limited sampling strategy for the estimation of mycophenolic acid area under the concentration time curve in adult renal transplant patients in the stable posttransplant period. Ther Drug Monit. 2010;32:136-140.
11. Mathew BS, Fleming DH, Prasanna S, et al. Mycophenolic acid estimation by pooled sampling: a novel strategy. Ther Drug Monit. 2010;32:141-144.
12. Kuypers DR, Le Meur Y, Cantarovich M, et al. Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation. Clin J Am Soc Nephrol. 2010;5:341-358.
13. Pescovitz MD, Guasch A, Gaston R, et al. Equivalent pharmacokinetics of mycophenolate mofetil in African-American and Caucasian male and female stable renal allograft recipients. Am J Transplant. 2003;3: 1581-1586.
14. Joy MS, Hilliard T, Hu Y, et al. Pharmacokinetics of mycophenolic acid in patients with lupus nephritis. Pharmacotherapy. 2009;29:7-16.
15. Neumann I, Fuhrmann H, Fang IF, et al. Association between mycophenolic acid 12-h trough levels and clinical endpoints in patients with autoimmune disease on mycophenolate mofetil. Nephrol Dial Transplant. 2008;23:3514-3520.
16. van Gelder T, Silva HT, de Fijter JW, et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation. 2008;86:1043-1051.